摘要
目的探讨FOLFOX化疗在结直肠癌肝转移手术治疗中的应用价值。方法对116例结直肠癌肝转移患者新辅助化疗的临床资料进行回顾性总结分析。结果 53例肝转移灶缩小,客观有效率(ORR)45.7%。其中21例(18.1%)获得根治性切除,中位生存时间29.2个月。结论术前新辅助化疗,使结直肠癌肝转移患者因肝转移灶的切除而延长了生存期。
Objective To evaluate the value of oxaliplatin,fluorouracil and leucovorin（FOLFOX） as neoadjuvant chemotherapy in operation of colorectal liver metastases patients.Methods The clinical data of 116 colorectal cancer patients with liver metastases were analyzed retrospectively.Results Data showed that the diameter and volume of focus of a liver metastases grew down in 53 patients.The objective response rate（ORR）was 45.7%.Being liver resected for colorectal liver metastases patients,it has been prolonged to 29.2 months for median survival in 21 patients.Conclusions Perioperative chemotherapy improves survival in colorectal liver metastases patients being liver resection for secondary tumors.
出处
《医药论坛杂志》
2011年第8期92-94,共3页
Journal of Medical Forum
关键词
结直肠癌肝转移
外科手术
化疗
中位生存时间
Colorectal liver metastases
Surgical resection
Chemotherapy
Median survival
